Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Antonia

Showing results (31-40 of 83) with videos related to

Pageof 9
Sort By:
Cancer Research|September 20, 2006
All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patientsNoweeda Mirza, Mayer Fishman, Ingo Fricke, et al.
Cancer|February 28, 2007
Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small cell and neuroendocrine carcinomasGilberto de Lima Lopes, Alberto Chiappori, George Simon, et al.
Patterns (New York, N.Y.)|July 18, 2022
Mistic: An open-source multiplexed image t-SNE viewerSandhya Prabhakaran, Chandler Gatenbee, Mark Robertson-Tessi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2007
Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancerGeorge Simon, Anupama Sharma, Xueli Li, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 16, 2010
Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanomaSteven E Finkelstein, Timothy Carey, Ingo Fricke, et al.
Lung Cancer (Amsterdam, Netherlands)|July 24, 2018
Induction chemoradiotherapy versus chemotherapy alone for superior sulcus lung cancerLary A Robinson, Tawee Tanvetyanon, Deanna Grubbs, et al.
Lung Cancer (Amsterdam, Netherlands)|September 9, 2018
Reply to Dickhoff et al. from authors of 'Induction chemoradiotherapy versus chemotherapy alone for superior sulcus lung cancer'Lary A Robinson, Tawee Tanvetyanon, Deanna Grubbs, et al.
The Lancet. Oncology|February 10, 2016
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b studyScott Antonia, Sarah B Goldberg, Ani Balmanoukian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2009
Phase I/II trial of tremelimumab in patients with metastatic melanomaLuis H Camacho, Scott Antonia, Jeffrey Sosman, et al.
International Journal of Cancer|December 15, 2010
Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytomaS Tariq Mahmood, Samuel Agresta, Carlos E Vigil, et al.
Pageof 9

Showing results (31-40 of 83) with videos related to

Sort By:
Pageof 9
Cancer Research|September 20, 2006
All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patientsNoweeda Mirza, Mayer Fishman, Ingo Fricke, et al.
Cancer|February 28, 2007
Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small cell and neuroendocrine carcinomasGilberto de Lima Lopes, Alberto Chiappori, George Simon, et al.
Patterns (New York, N.Y.)|July 18, 2022
Mistic: An open-source multiplexed image t-SNE viewerSandhya Prabhakaran, Chandler Gatenbee, Mark Robertson-Tessi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2007
Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancerGeorge Simon, Anupama Sharma, Xueli Li, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 16, 2010
Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanomaSteven E Finkelstein, Timothy Carey, Ingo Fricke, et al.
Lung Cancer (Amsterdam, Netherlands)|July 24, 2018
Induction chemoradiotherapy versus chemotherapy alone for superior sulcus lung cancerLary A Robinson, Tawee Tanvetyanon, Deanna Grubbs, et al.
Lung Cancer (Amsterdam, Netherlands)|September 9, 2018
Reply to Dickhoff et al. from authors of 'Induction chemoradiotherapy versus chemotherapy alone for superior sulcus lung cancer'Lary A Robinson, Tawee Tanvetyanon, Deanna Grubbs, et al.
The Lancet. Oncology|February 10, 2016
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b studyScott Antonia, Sarah B Goldberg, Ani Balmanoukian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2009
Phase I/II trial of tremelimumab in patients with metastatic melanomaLuis H Camacho, Scott Antonia, Jeffrey Sosman, et al.
International Journal of Cancer|December 15, 2010
Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytomaS Tariq Mahmood, Samuel Agresta, Carlos E Vigil, et al.
Pageof 9